CTI closes data set for endpoint analysis in Phase III lymphoma trial
The primary endpoint for the study is the complete remission (CR) and unconfirmed complete remission (uCR) rate in patients receiving either pixantrone or another single agent chemotherapeutic drug.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.